Kezar Life Sciences (NASDAQ:KZR) Price Target Cut to $11.00 by Analysts at Wells Fargo & Company

Kezar Life Sciences (NASDAQ:KZR) had its price target cut by Wells Fargo & Company from $20.00 to $11.00 in a research note published on Thursday,Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also issued research reports about the company. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Stock Performance

Shares of Kezar Life Sciences stock opened at $7.46 on Thursday. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $11.35. The business’s fifty day simple moving average is $7.20 and its 200-day simple moving average is $6.82. The firm has a market cap of $54.46 million, a PE ratio of -0.57 and a beta of 0.22. The company has a quick ratio of 9.58, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.25. Equities analysts forecast that Kezar Life Sciences will post -6.47 earnings per share for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Kezar Life Sciences by 15.0% during the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after acquiring an additional 81,678 shares in the last quarter. XTX Topco Ltd increased its holdings in Kezar Life Sciences by 256.1% during the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after purchasing an additional 37,504 shares during the period. Ikarian Capital LLC increased its holdings in Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after purchasing an additional 200,000 shares during the period. Stonepine Capital Management LLC increased its holdings in Kezar Life Sciences by 42.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock worth $1,153,000 after purchasing an additional 440,853 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Kezar Life Sciences during the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.